Login
News
A New Era in the Treatment of Chronic HCV Infection
08 June 2011In May 2011, the FDA has approved two new drugs to treat chronic hepatitis C (HCV) infection. The two drugs, Boceprevir (Victrelis) from Merck & Co. and Telaprevir (Incivek) from Vertex (in collaboration with Tibotec), both act as inhibitors of HCV's protease enzyme. This is the first time in...
New Treatments Available Soon for HCV Infection
03 May 2011On April 27 and 28, the FDA's Antiviral Drugs Advisory Committee reviewed all available data presented to support approval of two new molecules developed separately by Merck & Co. (initially by Schering-Plough) and Vertex Pharmaceuticals for the treatment of chronic HCV infection.
The two...
HIV can use ribonucleotides to replicate inside macrophages
01 February 2011In a paper published in Journal of Biological Chemistry (Dec. 10 issue), Kennedy et al. from University of Rochester Medical Center and Emory University reported evidence that HIV has developed an original strategy to replicate efficiently in non-dividing macrophages despite the absence of...
Conferences
Frontiers of Retrovirology 2011
Amsterdam, Netherlands (Mövenpick Hotel) October 3-5, 2011 www.frontiers-of-retrovirology.com
62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
San Francisco (CA), USA - November 4-8, 2011 http://www.aasld.org/lm/Pages/TheLiverMeeting2011.aspx
The Fifth International Workshop on HIV Persistence during Therapy
St Martin, West Indies - December 6-9, 2011 http://www.hiv-workshop.com/
62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
San Francisco (CA), USA - November 4-8, 2011 http://www.aasld.org/lm/Pages/TheLiverMeeting2011.aspx
The Fifth International Workshop on HIV Persistence during Therapy
St Martin, West Indies - December 6-9, 2011 http://www.hiv-workshop.com/
Frontiers of Retrovirology 2011
Amsterdam, Netherlands (Mövenpick Hotel) October 3-5, 2011 www.frontiers-of-retrovirology.com